STACEY BERG to Protein Kinase Inhibitors
This is a "connection" page, showing publications STACEY BERG has written about Protein Kinase Inhibitors.
Connection Strength
0.745
-
Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest New Drugs. 2013 Feb; 31(1):39-45.
Score: 0.298
-
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clin Cancer Res. 2019 06 01; 25(11):3229-3238.
Score: 0.119
-
A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer. 2018 12 01; 124(23):4548-4555.
Score: 0.116
-
Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models. Clin Cancer Res. 2018 05 01; 24(9):2159-2170.
Score: 0.111
-
Educational paper. The development of new therapies for pediatric oncology. Eur J Pediatr. 2011 May; 170(5):555-9.
Score: 0.067
-
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res. 2021 07 01; 27(13):3543-3548.
Score: 0.034